Preclinical CRO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service (Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology, Others), By Model Type (Patient Derived Organoid (PDO) Model, Patient derived xenograft model), By End-Use Industry (Biopharmaceutical Companies, Government and Academic Institutes, Medical Device Companies), By Region, Competition 2018-2028

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

 

Forecast Period

2024-2028

Market Size (2022)

USD 5.89 billion

CAGR (2023-2028)

8.53%

Fastest Growing Segment

Patient Derived Organoid (PDO) Model

Largest Market

North America

 

Market Overview

Global Preclinical CRO Market has valued at USD 5.89 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 8.53% through 2028. Preclinical CRO are colored substances that are applied in the form of an aqueous solution on various substrates. They serve as colorants in various industrial applications such as food processing, printing inks, wood stain, textile processing, and others. Preclinical CRO exhibit high selective absorptivity for liquids and substrates, making them superior to other color-imparting materials like pigments. Their exceptional absorption characteristics facilitate the modification of their physical and structural properties when applied on substrates. However, Preclinical CRO have low resistance to light and a relatively shorter shelf life. As a result, they are primarily used in surface coating, food, and printing applications that demand high levels of transparency in the manufacturing of finished products. Preclinical CRO can be categorized based on their solubility in a specific medium or substrate, including basic Preclinical CRO, fat-soluble Preclinical CRO, and metal complex Preclinical CRO.

 Key Market Drivers

Increasing Outsourcing Trends Drives the Market Growth

The increasing outsourcing trend is a significant driver behind the growth of the Global Preclinical Contract Research Organization (CRO) market. This trend involves pharmaceutical and biotechnology companies opting to delegate their preclinical research and development activities to specialized CROs rather than conducting them in-house. Outsourcing preclinical research allows pharmaceutical and biotechnology companies to save on various costs associated with maintaining in-house facilities, equipment, and personnel. CROs often have established infrastructure and expertise, enabling efficient and cost-effective execution of preclinical studies. By outsourcing preclinical research, companies can allocate their internal resources to core activities such as clinical trials, regulatory affairs, and commercialization. This streamlined focus enhances overall operational efficiency. Preclinical CROs are staffed with experts in various scientific disciplines, offering specialized knowledge and experience. Companies can tap into this expertise without having to build and maintain an extensive in-house team. CROs invest in state-of-the-art technologies and equipment for preclinical research. By outsourcing, companies gain access to these advanced tools without the need for significant capital investments. Outsourcing provides companies with flexibility to scale their preclinical activities up or down based on project needs. This adaptability is crucial for navigating the dynamic nature of drug development. Preclinical CROs often have established processes and workflows, which can lead to faster study execution and reduced development timelines. This acceleration is crucial for getting drugs to market more quickly.

Rising Number of Drugs In Preclinical Phases

The rising number of drugs in preclinical phases contributes to the growth of the Global Preclinical Contract Research Organization (CRO) market in several ways. As pharmaceutical and biotechnology companies continue to develop a larger pipeline of potential drug candidates, the demand for preclinical research and testing services provided by CROs increases. As more drug candidates enter preclinical phases, there is a greater need for conducting various preclinical studies, such as safety assessments, efficacy testing, and pharmacokinetics studies. CROs offer the capacity and specialized expertise to handle multiple projects simultaneously. Different drug candidates require different types of preclinical testing, ranging from small molecules to biologics and novel therapies. CROs often possess a diverse range of expertise to accommodate these varying needs, leading to increased outsourcing. Companies may not have the internal resources, equipment, or facilities required to conduct multiple preclinical studies concurrently. Outsourcing to CROs enables efficient resource allocation and optimization. The increasing number of drug candidates underscores the need for streamlined and accelerated preclinical development processes. CROs' established workflows and expertise can help expedite studies, enabling quicker progression to clinical phases. Managing many preclinical programs can be challenging for companies. CROs offer specialized risk management strategies and tools to navigate the complexities of preclinical research, thereby reducing the potential for costly failures.

Rising R&D Costs Drives the Market Growth

The rising costs of research and development (R&D) in the pharmaceutical and biotechnology industries are a significant driver behind the growth of the Global Preclinical Contract Research Organization (CRO) market. As R&D costs continue to escalate, companies are increasingly turning to preclinical CROs to optimize their drug development processes, improve cost-effectiveness, and enhance overall efficiency. The high costs associated with in-house preclinical research facilities, equipment, staffing, and operational expenses can strain a company's budget. Outsourcing to preclinical CROs offers a more cost-effective alternative, enabling companies to contain and manage their R&D expenses. By outsourcing preclinical studies to CROs, companies can leverage the CROs' established infrastructure, equipment, and experienced personnel, thereby minimizing the need for heavy capital investments and ongoing operational costs. Outsourcing preclinical work to CROs can help mitigate the financial risks associated with failed drug candidates. CROs conduct rigorous preclinical testing, identifying potential issues early in the development process and reducing the likelihood of expensive clinical trial failures. CROs often employ specialists in various scientific and regulatory fields, providing access to a broad range of expertise without the need for extensive in-house teams. This expertise can optimize study design, execution, and data interpretation. The complexity of regulatory requirements and the need for adherence to quality standards can contribute to R&D costs. Preclinical CROs are well-versed in navigating these regulatory landscapes, ensuring studies are conducted in compliance with guidelines. Efficient preclinical research conducted by CROs can accelerate the drug development process, enabling companies to move promising candidates into clinical trials more quickly. This speed-to-market can result in significant cost savings and revenue generation. Preclinical CROs offer a variety of services, such as safety assessments, efficacy testing, pharmacokinetics, toxicology studies, and more. Companies can choose specific services based on their needs, optimizing resource allocation.


Download Free Sample Report

Key Market Challenges

Regulatory Compliance and Quality Assurance

Regulatory compliance and quality assurance pose significant challenges to the Global Contract Research Organization (CRO) market, particularly in the context of preclinical research. The pharmaceutical and biotechnology industries are heavily regulated by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Ensuring that preclinical studies are conducted in strict accordance with these regulations is essential for obtaining regulatory approvals and advancing to clinical trials. Regulatory requirements can vary between regions and countries. Preclinical CROs working with clients from different geographic locations need to navigate and harmonize diverse regulatory frameworks, which can be complex and time-consuming. Failure to comply with regulatory guidelines can lead to delays, increased costs, or even the rejection of drug candidates in later development stages. CROs must maintain a thorough understanding of evolving regulations to minimize the risk of non-compliance.

Data Interpretation and Reporting

Data interpretation and reporting present significant challenges to the Global Contract Research Organization (CRO) market, particularly in the context of preclinical research. Accurate and meaningful data interpretation and reporting are essential for informed decision-making in drug development. Preclinical studies generate complex and multidimensional data. Interpreting this data requires a deep understanding of relevant scientific principles, statistical analyses, and biological context to draw accurate conclusions. Biological systems are inherently variable. CROs must account for biological variability in their data interpretation to differentiate true effects from background noise and to identify meaningful trends. Modern technologies generate vast amounts of data in preclinical studies. Managing and analyzing this "big data" can be overwhelming, requiring sophisticated bioinformatics tools and expertise. Incorrect data interpretation can lead to false positives (detecting effects that are not real) or false negatives (missing real effects). Both scenarios can have serious consequences for drug development decisions.

Communication and Collaboration

Communication and collaboration challenges can impact the Global Contract Research Organization (CRO) market, particularly in the context of preclinical research. Effective communication and collaboration between CROs and their clients are essential for successful project outcomes. Poor communication can lead to misaligned expectations between CROs and clients. If the client's goals and requirements are not clearly understood, it can result in deliverables that do not meet expectations. In an increasingly globalized industry, CROs and clients may come from different countries and cultures. Language barriers and cultural differences can hinder effective communication and collaboration. Preclinical studies often involve complex experimental designs and methodologies. Communicating these intricacies to clients and ensuring they understand the technical aspects can be challenging. Delays in communication can lead to project disruptions, missed deadlines, and increased costs. Clear and timely communication is crucial to keep projects on track. To address these challenges, CROs must prioritize clear, transparent, and proactive communication practices. They should establish robust communication channels, provide regular updates, and ensure that clients are well-informed about project progress.

Key Market Trends

Increase in the number of Virtual Trials

The increase in the number of virtual trials is a significant trend in the Global Contract Research Organization (CRO) market, transforming how clinical research is conducted. Virtual trials, also known as decentralized clinical trials, leverage technology to remotely collect data from participants, reducing the need for physical site visits. Virtual trials allow patients to participate from the comfort of their homes, increasing patient recruitment and retention rates. CROs are adapting their strategies to engage patients virtually through telehealth, wearables, and mobile apps. CROs are partnering with technology providers to integrate digital tools for remote data collection, patient monitoring, electronic informed consent, and telemedicine consultations. This requires expertise in selecting, implementing, and managing these technologies. CROs are implementing robust data management solutions to handle the large volumes of remote patient-generated data. This includes ensuring data integrity, security, and compliance with regulatory standards. Virtual trials reduce the dependence on physical trial sites, allowing CROs to conduct trials without traditional brick-and-mortar sites. This streamlines operations, enhances efficiency, and reduces costs associated with site infrastructure. Virtual trials enable access to a more diverse patient population, including those who may have been excluded due to geographic constraints. This expands the potential pool of participants and enhances the generalizability of trial results.

Segmental Insights

Service Insights

In 2022, the Preclinical CRO market was dominated by the Toxicology testing and is predicted to continue expanding over the coming years. Toxicology testing is a crucial and dominant segment within the Global Contract Research Organization (CRO) market, especially in the preclinical stage of drug development. Toxicology testing assesses the potential adverse effects of new compounds on living organisms, helping to determine their safety profiles before progressing to clinical trials. Ensuring the safety of potential drug candidates is a top priority for pharmaceutical and biotechnology companies. Toxicology studies provide critical data on the potential risks and hazards associated with new compounds. The segment is projected to experience the highest compound annual growth rate (CAGR) from 2023 to 2030.

Model Type Insight

In 2022, the Preclinical CRO market was dominated by PDO segment and is predicted to continue expanding over the coming years. PDO models are three-dimensional cell cultures derived from patient tissues, mimicking the complex architecture and functionality of organs more closely than traditional cell lines. This high level of patient relevance makes PDOs valuable tools for studying disease mechanisms, drug responses, and personalized treatments. The move toward personalized medicine requires the development of models that replicate patient-specific responses to treatments. PDO models enable researchers to study how individual patients' cells respond to different therapies, facilitating the development of tailored treatment strategies.

End-Use Industry Insights

In 2022, the Preclinical CRO market was dominated by biopharmaceutical companies’ segment and is predicted to continue expanding over the coming years. Biopharmaceutical companies often prioritize their core competencies, such as research, innovation, and commercialization. Outsourcing certain functions, including preclinical and clinical research, to CROs allows these companies to concentrate their internal resources on critical areas. CROs offer a cost-effective solution for biopharmaceutical companies. Outsourcing eliminates the need for heavy investments in infrastructure, equipment, personnel, and operational costs associated with in-house research activities. CROs provide specialized expertise and experience in conducting various aspects of drug development, including preclinical testing, clinical trials, data analysis, regulatory submissions, and more. Biopharmaceutical companies benefit from accessing these specialized skills without maintaining an extensive in-house team.


Download Free Sample Report

Regional Insights

The Asia Pacific region has established itself as the leader in the Global Preclinical CRO Market. established CROs focused on early drug discovery, like Charles River Laboratories or LabCorp. U.S. Preclinical Trial Outsourcing the U.S. preclinical trial outsourcing market is the largest because many biopharma companies prefer to outsource their preclinical trial to a CRO based in the United States in order to take advantage of the FDA-approved Investigational New Drug application.

Recent Developments

  • In February 2021, ICON Acquires PRA Health Sciences to Create a Global Leader in Healthcare Intelligence & Clinical Research. The consolidation combines two organizations that have a long-standing track record of strong growth and performance and are well-positioned to capitalize on this strength by leveraging the exceptional talent of both organizations to create greater value for patients, clients, staff and shareholders. The combination will meet the increasing demand for decentralised and hybrid trial services from a unique mix of mobile and connected healthcare platforms, a global network of sites, home health services, and wearables knowledge.
  • In November 2022, AppTec, a leading global provider of research, development and manufacturing services to the pharmaceutical, biotechnology and medical device industries for the advancement of discoveries and the delivery of innovative treatments to patients, today announced that it has been named a recipient of Frost & Sullivan’s 2022 Global Contract Research and Development and Manufacturing Company of the Year Awards. Frost & Sullivan is a global research and consulting firm that works with customers to help them drive growth. This is the 6th consecutive year that AppTec has received the award for leadership and innovative services.
  • In March 2023, Apollo™ is a cloud-based, industry-leading platform for drug developers to save time and improve the client experience. Today, Charles River Laboratories International, LLC (CRL) announced the launch of Apollo™, the industry’s first cloud-based, secure platform for drug development. Apollo’s suite of features includes Access to study data Study milestones Documentation Cost estimates Program planning tools Current capabilities include: Safety assessment Toxicology studies.

Key Market Players

  • Eurofins Scientific SE
  • PRA Health Sciences, Inc.
  • Wuxi AppTec
  • Medpace, Inc.
  • Charles River Laboratories International, Inc.
  • PPD (Thermo Fisher Scientific, Inc.)
  • SGA SA
  • Intertek Group Plc (IGP)
  • LABCORP Inc
  • Crown Bioscience Inc

 By Service

By Model Type

By End User

By Region
  • Bioanalysis and DMPK studies
  • Toxicology Testing
  • Compound Management
  • Chemistry
  • Safety Pharmacology
  • Others
  • Patient Derived Organoid (PDO) Model
  • Patient derived xenograft model
  • Biopharmaceutical Companies
  • Government and Academic Institutes
  • Medical Device Companies
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa
Report Scope:

In this report, the Global Preclinical CRO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Preclinical CRO Market, By Service:

o   Bioanalysis and DMPK studies

o   Toxicology Testing

o   Compound Management

o   Chemistry

o   Safety Pharmacology

o   Others

  • Preclinical CRO Market, By Model:

o   Patient Derived Organoid (PDO) Model

o   Patient derived xenograft model

  • Preclinical CRO Market, By End-User:

o   Biopharmaceutical Companies

o   Government and Academic Institutes

o   Medical Device Companies

  • Global Preclinical CRO Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preclinical CRO Market.

Available Customizations:

Global Preclinical CRO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Preclinical CRO Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.   Markets Covered

1.2.2.   Years Considered for Study

1.2.3.   Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Preclinical CRO Market Outlook

5.1.  Market Size & Forecast

5.1.1.   By Value 

5.2.  Market Share & Forecast

5.2.1.   By Service (Bioanalysis and DMPK Studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology, Others)

5.2.2.     By Model Type (Patient Derived Organoid (PDO) Model, Patient derived xenograft model)

5.2.3.     By End-Use Industry (Biopharmaceutical Companies, Government and Academic Institutes, Medical Device Companies)

5.2.4.   By Company (2022)

5.2.5.   By Region

5.3.  Market Map

6.    North America Preclinical CRO Market Outlook

6.1.  Market Size & Forecast          

6.1.1.   By Value 

6.2.  Market Share & Forecast

6.2.1.   By Service

6.2.2.   By Model Type

6.2.3.   By End-Use Industry

6.2.4.   By Country

6.3.  North America: Country Analysis

6.3.1.   United States Preclinical CRO Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1.               By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1.               By Service

6.3.1.2.2.               By Model Type

6.3.1.2.3.               By End-Use Industry

6.3.2.   Mexico Preclinical CRO Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1.               By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1.               By Service

6.3.2.2.2.               By Model Type

6.3.2.2.3.               By End-Use Industry

6.3.3.   Canada Preclinical CRO Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1.               By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1.               By Service

6.3.3.2.2.               By Model Type

6.3.3.2.3.               By End-Use Industry

7.    Europe Preclinical CRO Market Outlook

7.1.  Market Size & Forecast          

7.1.1.   By Value 

7.2.  Market Share & Forecast

7.2.1.   By Service

7.2.2.   By Model Type

7.2.3.   By End-Use Industry 

7.2.4.   By Country

7.3.  Europe: Country Analysis

7.3.1.   France Preclinical CRO Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1.               By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1.               By Service

7.3.1.2.2.               By Model Type

7.3.1.2.3.               By End-Use Industry

7.3.2.   Germany Preclinical CRO Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1.               By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1.               By Service

7.3.2.2.2.               By Model Type

7.3.2.2.3.               By End-Use Industry

7.3.3.   United Kingdom Preclinical CRO Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1.               By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1.               By Service

7.3.3.2.2.               By Model Type

7.3.3.2.3.               By End-Use Industry

7.3.4.   Italy Preclinical CRO Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1.               By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1.               By Service

7.3.4.2.2.               By Model Type

7.3.4.2.3.               By End-Use Industry

7.3.5.   Spain Preclinical CRO Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1.               By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1.               By Service

7.3.5.2.2.               By Model Type

7.3.5.2.3.               By End-Use Industry

8.    Asia-Pacific Preclinical CRO Market Outlook

8.1.  Market Size & Forecast          

8.1.1.   By Value 

8.2.  Market Share & Forecast

8.2.1.   By Service

8.2.2.   By Model Type

8.2.3.   By End-Use Industry 

8.2.4.   By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.   China Preclinical CRO Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1.               By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1.               By Service

8.3.1.2.2.               By Model Type

8.3.1.2.3.               By End-Use Industry

8.3.2.   India Preclinical CRO Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1.               By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1.               By Service

8.3.2.2.2.               By Model Type

8.3.2.2.3.               By End-Use Industry

8.3.3.   South Korea Preclinical CRO Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1.               By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1.               By Service

8.3.3.2.2.               By Model Type

8.3.3.2.3.               By End-Use Industry

8.3.4.   Japan Preclinical CRO Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1.               By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1.               By Service

8.3.4.2.2.               By Model Type

8.3.4.2.3.               By End-Use Industry

8.3.5.   Australia Preclinical CRO Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1.               By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1.               By Service

8.3.5.2.2.               By Model Type

8.3.5.2.3.               By End-Use Industry

9.    South America Preclinical CRO Market Outlook

9.1.  Market Size & Forecast          

9.1.1.   By Value 

9.2.  Market Share & Forecast

9.2.1.   By Service

9.2.2.   By Model Type

9.2.3.   By End-Use Industry 

9.2.4.   By Country

9.3.  South America: Country Analysis

9.3.1.   Brazil Preclinical CRO Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1.               By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1.               By Service

9.3.1.2.2.               By Model Type

9.3.1.2.3.               By End-Use Industry

9.3.2.   Argentina Preclinical CRO Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1.               By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1.               By Service

9.3.2.2.2.               By Model Type

9.3.2.2.3.               By End-Use Industry

9.3.3.   Colombia Preclinical CRO Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1.               By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1.               By Service

9.3.3.2.2.               By Model Type

9.3.3.2.3.               By End-Use Industry

10.  Middle East and Africa Preclinical CRO Market Outlook

10.1.              Market Size & Forecast

10.1.1.                By Value 

10.2.              Market Share & Forecast

10.2.1.                By Service

10.2.2.                By Model Type

10.2.3.                By End-Use Industry 

10.2.4.                By Country

10.3.              MEA: Country Analysis

10.3.1.                South Africa Preclinical CRO Market Outlook

10.3.1.1.              Market Size & Forecast

10.3.1.1.1.             By Value

10.3.1.2.              Market Share & Forecast

10.3.1.2.1.             By Service

10.3.1.2.2.             By Model Type

10.3.1.2.3.             By End-Use Industry

10.3.2.                Saudi Arabia Preclinical CRO Market Outlook

10.3.2.1.              Market Size & Forecast

10.3.2.1.1.             By Value

10.3.2.2.              Market Share & Forecast

10.3.2.2.1.             By Service

10.3.2.2.2.             By Model Type

10.3.2.2.3.             By End-Use Industry

10.3.3.                UAE Preclinical CRO Market Outlook

10.3.3.1.              Market Size & Forecast

10.3.3.1.1.             By Value

10.3.3.2.              Market Share & Forecast

10.3.3.2.1.             By Service

10.3.3.2.2.             By Model Type

10.3.3.2.3.             By End-Use Industry

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

12.1.              Recent Developments

12.2.              Product Launches

12.3.              Mergers & Acquisitions

13.  PESTLE Analysis

14.  Porter’s Five Forces Analysis

14.1.              Competition in the Industry

14.2.              Potential of New Entrants

14.3.              Power of Suppliers

14.4.              Power of Customers

14.5.              Threat of Substitute Product

15.  Competitive Landscape

15.1.              Business Overview

15.2.              Company Snapshot

15.3.              Products & Services

15.4.              Financials (In case of listed companies)

15.5.              Recent Developments

15.6.              SWOT Analysis

15.6.1.  Eurofins Scientific SE

15.6.2.  PRA Health Sciences, Inc.

15.6.3.  Wuxi AppTec

15.6.4.  Medpace, Inc.

15.6.5.  Charles River Laboratories International, Inc.

15.6.6.  PPD (Thermo Fisher Scientific, Inc.)

15.6.7.  SGA SA

15.6.8.  Intertek Group Plc (IGP)

15.6.9.  LABCORP Inc

15.6.10.                Crown Bioscience Inc

16.  Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Preclinical CRO Market was estimated to be USD 5.89 billion in 2022.

down-arrow

Eurofins Scientific SE, PRA Health Sciences, Inc., Wuxi AppTec, Medpace, Inc., Charles River Laboratories International, Inc., PPD (Thermo Fisher Scientific, Inc.), SGA SA, Intertek Group Plc (IGP), LABCORP Inc, Crown Bioscience Inc are some of the key players operating in the Global Preclinical CRO Market.

down-arrow

Data Interpretation and Reporting and Regulatory Compliance and Quality Assurance are the major challenges faced by the Global Preclinical CRO Market in the upcoming years.

down-arrow

Rising number of drugs in clinical phase and Increasing Outsourcing Trends is majorly driving the demand for the global Preclinical CRO market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Global Preclinical CRO Market to Grow with a CAGR of 8.53% through 2028

Oct, 2023

Increasing in the number of Pharmacokinetics and Pharmacodynamics (PK/PD) Studies support the Preclinical CRO are the major drivers for the Global Preclinical CRO Market.

Why Choose Us